GWPH News and Press, GW Pharmaceuticals Plc From 02/25/20

GW Pharmaceuticals (NASDAQ: GWPH ) Q4 net loss of $24.9M, or 7 cents per share, narrows from net loss of $71.9M, or 20 cents per share, in the year-ago quarter. More news on: GW Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Read more ...

GW Pharmaceuticals (NASDAQ: GWPH ): Q4 GAAP EPS of -$0.07 misses by $0.03 . Revenue of $109.1M  beats by $4.78M . Press Release More news on: GW Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news,

- Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year - - Total Epidiolex ® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of sales - - Conference call today at 4:30 ...

February 24, 2020 Palm Beach, FL – February 24, 2020 — Over the next five years, the global CBD market is expected to accelerate to $23.6 billion, according to Grand View Research .  All thanks to the growing adoption of CBD-infused products in industries such as...

There's no sugarcoating it -- marijuana stocks had an awful 2019. A combination of persistent supply issues throughout much of Canada, high tax rates in a number of key U.S. markets, and a resilient black market presence made life very difficult for cannabis stocks last year, with quite a few en...

LONDON and CARLSBAD, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief E...

Psychedelic drugs are just beginning a cultural renaissance. According to CTV News , Johns Hopkins is expanding its testing of psilocybin and other psychedelics, for issues including obsessive compulsive disorder, post-traumatic stress disorder, opioid use disorder, alcoholism and anorexia n...

Thesis Summary Zogenix, Inc. ( ZGNX ) is a pharmaceutical company that develops and commercializes therapies for rare diseases. Recently, some “disappointing” data on Fintepla sent the stock tumbling over 30%. However, I believe that the market has overreacted to the results,...

The CBD market is seen by experts as underserved, ready for exponential growth, and channeling to consumers who want to try CBD product in the future. It reflects a still young market ready to explode in sales. Some research projects a 125% YOY rate of growth over the next five years — ...

The psilocybin mushroom story isn’t likely peak any time soon. Over the last few months, Denver, Oakland, and Santa Cruz just decriminalized the possession of products containing psilocybin or psilocin. Washington, D.C. could be next. Major institutions are even studying its use for ...